Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double-blinded, randomized clinical trial in Sri Lanka

Abstract Background Oral lichen planus (OLP) is a mucocutaneous autoimmune disease with T-cell mediation. Corticosteroids are considered as a first choice in OLP and should be used for a long period with a subsequent increase in dose since the disease has a chronic and recalcitrant nature. There have been efforts to use alternative therapies due to the Corticosteroid’s side effects. Curcumin is a non-toxic natural product with different effects on various oral diseases. It demonstrates antioxidant, anti-inflammatory, antimicrobial, and anticarcinogenic activities. It seems that Curcumin can be used as a proper alternative for Corticosteroid treatments. To overcome limitations in the bioavailability of Curcumin, the therapeutic effect of oral Nano-Curcumin was evaluated for the first time. Methods Sixty OLP patients were included in this double-blinded randomized clinical trial. The patients were randomly divided into two groups and received either ‘Nano-Curcumin 80 mg’ or ‘Prednisolone 10 mg’ treatments for 1 month. The patients should take one capsule after having their breakfast. The VAS scale was used to analyze pain severity and burning sensation. To assess lesion size the Thongprasom scale was employed. Repeated measures and independent t-tests, as well as LSD paired-test, were used to analyze the data. Results Data from 57 patients were analyzed. The level of pain, burning sensation, and OLP lesions decreased in both groups of Curcumin and Prednisolone and no statistically significant difference was observed between the two groups. Conclusion Despite many studies conducted to find an effective approach for managing OLP, the results have often been unsatisfactory. In comparison with previous studies, current results clarify the importance of Nano-Curcumin bioavailability in therapeutic effects. Pain VAS and lesion size were decreased with oral Curcumin. The results have shown that oral Curcumin can be used as an alternative therapy for OLP in patients with the contraindicated Corticosteroids or should be used with caution. Oral Curcumin can be used in preventing the recurrence of OLP lesions after the treatment and initial control. Moreover, the amount of Curcumin dose is more important than its use duration in improving OLP. Trial registration IRCT, IRCT20100101002950N5. Registered 9 February 2019, https://www.irct.ir/trial/36704.

Download Full-text

Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)

Case Medical Research ◽

10.31525/ct1-nct04193748 ◽

2019 ◽

Author(s):

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Lichen Planus ◽

Oral Lichen Planus ◽

Oral Lichen

Download Full-text

Comparative efficacy of topical aloe vera and low-level laser therapy in the management of oral lichen planus: a randomized clinical trial

Lasers in Medical Science ◽

10.1007/s10103-021-03480-1 ◽

2021 ◽

Author(s):

Girish Bhatt ◽

Sunita Gupta ◽

Sujoy Ghosh

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Laser Therapy ◽

Lichen Planus ◽

Oral Lichen Planus ◽

Aloe Vera ◽

Low Level Laser Therapy ◽

Comparative Efficacy ◽

Level Laser ◽

Oral Lichen

Download Full-text

Analysis of the Efficacy of Two Treatment Protocols for Patients with Symptomatic Oral Lichen Planus: A Randomized Clinical Trial

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18010056 ◽

2020 ◽

Vol 18 (1) ◽

pp. 56

Author(s):

Simona Santonocito ◽

Alessandro Polizzi ◽

Rocco De Pasquale ◽

Vincenzo Ronsivalle ◽

Antonino Lo Giudice ◽

...

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Lichen Planus ◽

Oral Lichen Planus ◽

Pain Scale ◽

Oral Solution ◽

Wilcoxon Test ◽

Treatment Protocols ◽

Anti Inflammatory ◽

Oral Lichen

Oral lichen planus (OLP) is a chronic, inflammatory, immune-mediated disease, which can alter the quality of life of patients. The aim of this randomized clinical trial was to compare the therapeutic efficacy of clobetasol oral gel 0.05% versus an anti-inflammatory in oral solution (mouthwash) in the management of patients suffering from symptomatic OLP. The secondary objective was to analyze which one of the two treatments induced a greater risk of developing side effects. Forty patients were assigned (20 patients for group), through a randomized design, to receive clobetasol gel 0.05% or an anti-inflammatory mouthwash, which contains calcium hydroxide, hyaluronic acid, umbelliferone and oligomeric pro-anthocyanidins) for three months. At baseline (T0) and after 3 months (T1), patients underwent dental and dermatological examinations to assess their symptoms (Numerical Pain Scale (NRS) score) and signs (Thongprasom score). Data were calculated using T-test for the dependent variable, Wilcoxon test and Mann-Whitney u test. Both clobetasol and anti-inflammatory resulted in a statistically significant reduction of signs, (p < 0.001 and p = 0.02, respectively) and symptoms (p < 0.001 for clobetasol and p = 0.02 for anti-inflammatory). In conclusion, the results evidenced that, compared to clobetasol, the anti-inflammatory was less effective in determining the reduction of signs and symptom in OLP patients.

Download Full-text